Other institutional investors have also increased or decreased their holdings in BIIB. In the fourth quarter, Norges Bank acquired a new stake in Biogen valued around $373,125,000. In the fourth quarter, Southeastern Asset Management Inc. TN acquired a new investment in Biogen for around $205,977,000. In the first quarter, RA Capital Management L.P. acquired a new investment in Biogen.
Biogen Trading Up 1.0% On Wednesday, shares of NASDAQ BIIB started at $197.79. Biogen Inc.'s 1 year high is $291.54 and its 1 year low is $187.16. The stock has a market capitalization of $28.70 billion, a price-to-earnings-growth ratio of 1.20, a P/E ratio of 14.11, and a beta of 0.43. The company's 50-day and 200-day moving averages are both $207.87 and $207.01, respectively. Debt-to-equity ratio for the firm is 0.53; current ratio is 1.94; quick ratio is 1.68.
On Wednesday, July 20th, Biogen (NASDAQ:BIIB - Get Rating) released its most recent quarterly earnings report. The biotechnology business outperformed analysts' consensus expectations by $1.16, announcing $5.25 earnings per share (EPS) for the quarter. Net margin for Biogen was 19.36%, while return on equity was 22.36%. In contrast to experts' projections of $2.48 billion, the company's revenue for the quarter was $2.59 billion. The business had $5.68 EPS for the same time period previous year. The income for Biogen decreased 6.7% from the previous year. Sell-side analysts collectively anticipate 16.45 EPS for Biogen Inc.'s current fiscal year.
New Price Targets are Set by Analysts
Numerous research organizations have published reports on BIIB. In a research report published on Wednesday, July 27th, StockNews.com raised shares of Biogen from a "buy" rating to a "strong-buy" rating. On Monday, September 12th, Stifel Nicolaus dropped their target price on shares of Biogen from $230.00 to $223.00 and gave the stock a "hold" rating. In a research report published on Wednesday, July 20th, Royal Bank of Canada decreased their target price on shares of Biogen from $264.00 to $259.00. On Monday, July 18th, Oppenheimer raised their price target on shares of Biogen from $225.00 to $230.00 and rated the stock with a "outperform" recommendation. The price target set by Barclays for shares of
About Biogen
Biogen Inc. finds, creates, produces, and distributes medicines for neurological and neurodegenerative illnesses. The business provides SPINRAZA for spinal muscular atrophy, TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS), as well as FUMADERM for plaque psoriasis.
Post a Comment